Delivery Order SPE2DR25D3104-SPE2DR26FE9JM
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on December 22, 2025, by the Defense Logistics Agency (DLA) for the supply of Zepbound 12.5 mg/0.5 mL pens with a ceiling value of $32,773.68. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of December 23, 2025, and was competitively awarded with no set-aside designation. This delivery order is issued under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $48,084.36 by the Defense Logistics Agency on December 16, 2025, for the supply of Zepbound 15 mg/0.5 ml pens. The contract is a firm fixed price delivery order with an ultimate completion date of December 17, 2025, and was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $46,892.88 by the Defense Logistics Agency on December 3, 2025, with an ultimate completion date of December 4, 2025. The contract covers the supply of Zepbound 5 mg/0.5 mL pens in 0.5 mL quantities under a firm fixed-price arrangement with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency valued at $8,793.11 for Zepbound 7.5 mg/0.5 mL pen injections. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of January 23, 2026, and was competitively awarded without set-aside restrictions. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $2,077.99 by the Defense Logistics Agency (DLA) on December 17, 2025, for the supply of Zepbound 15 mg/0.5 mL pen injections. This competitively awarded, firm fixed-price contract is classified as a child delivery order and will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of December 18, 2025. The award represents a continuation of AmerisourceBergen's substantial...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $8,478.28 by the Defense Logistics Agency on August 14, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. The contract utilizes firm fixed pricing and is classified as a non-set-aside, competitively awarded delivery order with an ultimate completion date of August 15, 2025. This award falls under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $4,710.68 to Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) on January 7, 2026, for the supply of Zepbound 10 mg/0.5 mL pens. This competitive, firm fixed-price delivery order is scheduled for ultimate completion on January 8, 2026, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order under Amerisourcebergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $8,337.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 20, 2026, for the supply of Zepbound 5 mg/0.5 mL pens with a completion date of January 21, 2026. The award was issued on a non-set-aside, competitive basis and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $15,743.09 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on January 5, 2026, with completion scheduled for January 6, 2026. This competitively awarded, firm fixed-price delivery order represents a pharmaceutical supply fulfillment under the company's broader pharmaceutical support framework. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor within the Defense...
- The Defense Logistics Agency awarded a $4,273.44 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors with an ultimate completion date of August 18, 2025. This is a non-set-aside competitive award leveraging AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle that runs through December 2026....
- SPE2DR25D3104Indefinite Delivery Contract
- SPE2DR25D3104-SPE2DR26FE9JMDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $4,821.96 by the Defense Logistics Agency on January 22, 2026, for the supply of Zepbound 15 mg/0.5 mL pens. The award was made on a firm fixed-price basis with no set-aside designation, indicating competition on a full and open basis. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. The Defense Logistics Agency procures pharmaceutical products and medical supplies to support military treatment facilities, veteran healthcare programs, and other federal medical institutions globally. AmerisourceBergen's parent company, Cencora, Inc. (doing business as AmerisourceBergen), holds the primary IDC with DLA through December 31, 2031, and has demonstrated consistent capability in fulfilling federal contracts for essential medications across multiple therapeutic domains. This specific delivery order for Zepbound, a diabetes medication, reflects DLA's ongoing procurement of specialized pharmaceutical commodities required by military healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 1/21/26 |